Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(4.70)
# 158
Out of 5,120 analysts
24
Total ratings
66.67%
Success rate
41.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OVID Ovid Therapeutics | Initiates: Buy | $3 | $1.51 | +98.68% | 1 | Dec 11, 2025 | |
| CING Cingulate | Maintains: Buy | $17 → $16 | $6.11 | +161.87% | 4 | Nov 19, 2025 | |
| PYPD PolyPid | Maintains: Buy | $10 → $9 | $4.87 | +84.80% | 3 | Nov 13, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $12 → $13 | $23.09 | -43.70% | 3 | Nov 12, 2025 | |
| RNA Avidity Biosciences | Initiates: Buy | $62 | $72.74 | -14.76% | 1 | Sep 17, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $7 → $3 | $0.29 | +925.29% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.55 | +447.35% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $1.78 | +237.08% | 3 | Aug 13, 2025 | |
| CRVO CervoMed | Reiterates: Buy | $20 → $16 | $4.87 | +228.54% | 4 | Aug 12, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $11.85 | +144.73% | 1 | Dec 5, 2024 |
Ovid Therapeutics
Dec 11, 2025
Initiates: Buy
Price Target: $3
Current: $1.51
Upside: +98.68%
Cingulate
Nov 19, 2025
Maintains: Buy
Price Target: $17 → $16
Current: $6.11
Upside: +161.87%
PolyPid
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $4.87
Upside: +84.80%
Capricor Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $23.09
Upside: -43.70%
Avidity Biosciences
Sep 17, 2025
Initiates: Buy
Price Target: $62
Current: $72.74
Upside: -14.76%
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $7 → $3
Current: $0.29
Upside: +925.29%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.55
Upside: +447.35%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $1.78
Upside: +237.08%
CervoMed
Aug 12, 2025
Reiterates: Buy
Price Target: $20 → $16
Current: $4.87
Upside: +228.54%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $11.85
Upside: +144.73%